Association of BRAF V600E Mutation with Poor Clinicopathological Outcomes in 500 Consecutive Cases of Papillary Thyroid Carcinoma
Cristiana Lupi,Riccardo Giannini,Clara Ugolini,Agnese Proietti,Piero Berti,Michele Minuto,Gabriele Materazzi,Rossella Elisei,Massimo Santoro,Paolo Miccoli,Fulvio Basolo +10 more
TLDR
The data suggest that BRAF V600E mutation is associated with high-risk PTC and in particular in follicular variant with invasive tumor growth.Abstract:
Context: Because very few studies have examined the correlation between BRAF mutations and clinicopathological features of papillary thyroid carcinoma (PTC), we analyzed here a large and homogeneous cohort of patients with PTC for the presence of the BRAF mutation. Objective: We examined BRAF mutations in a consecutive series of 500 PTC patients who underwent surgery in the Department of Surgery of the University of Pisa, and we correlated the presence of the mutation with clinicopathological parameters of the patients: age, gender, tumor size, presence of tumor capsule, extrathyroidal invasion, multicentricity, presence of node metastases, and tumor class. Design: BRAF (exon 15) mutation was examined by PCR-single strand conformational polymorphism followed by DNA sequencing in laser-capture microdissected tissue samples. Results: In this study, BRAF mutation was found in 219 of 500 cases (43.8%). In particular, we found the most common BRAF V600E mutation in 214 cases (42.8%), BRAF K601E mutation in thr...read more
Citations
More filters
Journal ArticleDOI
Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors
Yuri E. Nikiforov,Raja R. Seethala,Giovanni Tallini,Zubair W. Baloch,Fulvio Basolo,Lester D.R. Thompson,Justine A. Barletta,Bruce M. Wenig,Abir Al Ghuzlan,Kennichi Kakudo,Thomas J. Giordano,Venancio Avancini Ferreira Alves,Elham Khanafshar,Sylvia L. Asa,Adel K. El-Naggar,William E. Gooding,Steven P. Hodak,Ricardo V. Lloyd,Guy Maytal,Ozgur Mete,Marina N. Nikiforova,Vania Nosé,Mauro Papotti,David N. Poller,Peter M. Sadow,Arthur S. Tischler,R. Michael Tuttle,Kathryn B. Wall,Virginia A. LiVolsi,Gregory W. Randolph,Ronald Ghossein +30 more
TL;DR: Thyroid tumors currently diagnosed as noninvasive EFVPTC have a very low risk of adverse outcome and should be termed NIFTP, and this reclassification will affect a large population of patients worldwide and result in a significant reduction in psychological and clinical consequences associated with the diagnosis of cancer.
Journal ArticleDOI
BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.
TL;DR: It has become clearer that BRAF mutation will likely have significant impact on the clinical management of PTC and new mitogen extracellular kinase (MEK) inhibitors developed recently are particularly promising therapeutic agents for thyroid cancer.
Journal ArticleDOI
Molecular genetics and diagnosis of thyroid cancer
TL;DR: Somatic mutations and other molecular alterations have been recognized as helpful diagnostic and prognostic markers for thyroid cancer and are beginning to be introduced into clinical practice, to offer a valuable tool for the management of patients with thyroid nodules.
Journal ArticleDOI
Thyroid Cancer Epidemiology and Prognostic Variables
TL;DR: This paper will discuss this rising trend in incidence with an analysis of the possible reasons for the increase, and explore the factors that portend a worse prognosis for the individual patient.
Journal ArticleDOI
The association of the BRAFV600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer
Tae Hyuk Kim,Young Joo Park,Young Joo Park,Jung Ah Lim,Hwa Young Ahn,Eun Kyung Lee,You Jin Lee,Kyung Won Kim,Seo kyung Hahn,Yeo Kyu Youn,Kwang Hyun Kim,Bo Youn Cho,Do Joon Park +12 more
TL;DR: The effects of the BRAFV600E mutation on prognostic factors and poor clinical outcomes in papillary thyroid cancer (PTC) have not been fully quantified and a comprehensive meta‐analysis was performed.
References
More filters
Journal ArticleDOI
Mutations of the BRAF gene in human cancer
Helen Davies,Graham R. Bignell,Charles Cox,Philip J. Stephens,Sarah Edkins,S. M. Clegg,Jon W. Teague,Hayley Woffendin,Mathew J. Garnett,William Bottomley,Neil Davis,Ed Dicks,Rebecca Ewing,Yvonne Floyd,Kristian Gray,S. Hall,Rachel Hawes,Jaime Hughes,Vivian Kosmidou,Andrew Menzies,Catherine Mould,Adrian Parker,Claire Stevens,Stephen Watt,Steven Hooper,Rebecca Wilson,Hiran Jayatilake,Barry A. Gusterson,Colin Cooper,Janet Shipley,Darren Hargrave,Kathy Pritchard-Jones,Norman J. Maitland,Georgia Chenevix-Trench,Gregory J. Riggins,Darell D. Bigner,Giuseppe Palmieri,Antonio Cossu,Adrienne M. Flanagan,Andrew G. Nicholson,Judy W. C. Ho,Suet Yi Leung,Siu Tsan Yuen,Barbara L. Weber,Hilliard F. Seigler,Timothy L. Darrow,Hugh Paterson,Richard Marais,Christopher J. Marshall,Richard Wooster,Michael R. Stratton,P. Andrew Futreal +51 more
TL;DR: BRAF somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers, with a single substitution (V599E) accounting for 80%.
Journal ArticleDOI
Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.
TL;DR: Following 131I therapy, whether given for thyroid remnant ablation or cancer therapy, recurrence and the likelihood of cancer death were reduced by at least half, despite the existence of more adverse prognostic factors in patients given 131I.
Journal ArticleDOI
Cancer statistics, 1997
Journal ArticleDOI
Papillary and follicular thyroid carcinoma.
TL;DR: Treatment of recurrences is based mainly on surgery and 131I treatment, and the recent availability of recombinant human thyroid stimulating hormone has greatly improved the quality of the patient's life during follow-up.
Journal ArticleDOI
Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma : benefits and limits of radioiodine therapy
Cosimo Durante,Nadia Haddy,Eric Baudin,Sophie Leboulleux,D. Hartl,Jean-Paul Travagli,Bernard Caillou,Marcel Ricard,Jean Lumbroso,F. de Vathaire,Martin Schlumberger +10 more
TL;DR: Thyroxine treatment is highly effective in younger patients with (131)I uptake and with small metastases and should be treated until the disappearance of any uptake or until a cumulative activity of 22 GBq has been administered.
Related Papers (5)
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer
Mingzhao Xing,William H. Westra,Ralph P. Tufano,Yoram Cohen,Eli Rosenbaum,Kerry J. Rhoden,Kathryn A. Carson,Vasily Vasko,A Larin,Giovanni Tallini,Sara M. Tolaney,Elizabeth H. Holt,Pei Hui,Christopher B. Umbricht,Shehzad Basaria,Marge Ewertz,Anthony P. Tufaro,Joseph A. Califano,Matthew D. Ringel,Martha A. Zeiger,David Sidransky,Paul W. Ladenson +21 more